Abstract 1604P
Background
The Global Cancer Coalitions Network (GCCN), established in May 2020, collectively represents over 750 cancer patient organisations representing over 14 million patients around the world. Cancer services have faced challenges as a result of COVID-19, including suspension of screening and diagnostic services; delays in diagnosis leading to higher mortality rates; cancellation/deferral of life-saving treatments; changes in treatment regimens and suspension of vital research. Substantial increases in the number of avoidable cancer deaths are to be expected as a result of diagnostic delays due to the COVID-19 pandemic.
Methods
6 global cancer coalitions surveyed their member organisations in December 2020.
Results
Among 104 organisations from 46 countries representing advanced breast, bladder, colorectal, lymphoma, ovarian, and pancreatic cancer patient groups: · Demand for services has increased · 2/3 organisations experienced a fall in income from December 2020, averaging -48% · Over 1 in 10 organisations have closed temporarily, and some permanently · Only 1 in 10 organisations believe their 2021 income will return to levels seen before the pandemic · Almost half report that their ability to operate is under threat · Half do not have access to any national funding schemes to ensure operation during the pandemic · Staff shrunk -20%; volunteer numbers -70% · <20% organisations report normalised cancer services in December 2020; more respondents report services are “worse than ever” · Patient distress, isolation and financial hardship have increased markedly.
Conclusions
For organisations providing support to cancer patients, declining income, the need to reduce staff and move to virtual working practices has added strain while demand for support due to the pandemic has increased. Emergency support, including funding, must be made available to these organisations to ensure that the needs of cancer patients worldwide continue to be met.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.